Canada markets open in 9 hours 25 minutes

WPD Pharmaceuticals Inc. (WBIO.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.3500-0.0100 (-2.78%)
At close: 2:45PM EST

WPD Pharmaceuticals Inc.

789 West Pender Street
Suite 1080
Vancouver, BC V6C 1H2
604 428 7050

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Mariusz OlejniczakChief Exec. Officer45.82kN/AN/A
Mr. Liam Lake CorcoranCanadian VP of Legal, Corp. Sec. & Director69.46kN/AN/A
Dr. Waldemar Priebe Ph.D.Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Mr. Michael MalanaChief Financial OfficerN/AN/AN/A
Ms. Beata Pajak Eng., Ph.D.Chief Scientific OfficerN/AN/AN/A
Mr. Marek Sipowicz M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious disease. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat CNS tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of GBM, melanoma, and other cancers that is in the pre-clinical trial; and Annamycin to treat AML and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is based in Vancouver, Canada.

Corporate Governance

WPD Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.